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Abstract: Using a modelling approach, this study aimed to (i) examine whether the pharmacodynamics of the analgesic and anti-
hyperalgesic effects of morphine differ; (ii) investigate the influence of demographic, pain sensitivity and genetic (OPRM1) vari-
ables on between-subject variability of morphine pharmacokinetics and pharmacodynamics in human experimental pain models.
The study was a randomized, double-blind, 5-arm, cross-over, placebo-controlled study. The psychophysical cutaneous pain tests,
electrical pain tolerance (EPTo) and secondary hyperalgesia areas (2HA) were studied in 28 healthy individuals (15 males). The
subjects were chosen based on a previous trial where 100 subjects rated (VAS) their pain during a heat injury (47°C, 7 min.,
12.5 cm2). The 33% lowest- and highest pain-sensitive subjects were offered participation in the present study. A two-compart-
ment linear model with allometric scaling for weight provided the best description of the plasma concentration–time profile of
morphine. Changes in the EPTo and 2HA responses with time during the placebo treatment were best described by a linear
model and a quadratic model, respectively. The model discrimination process showed clear evidence for adding between-occa-
sion variability (BOV) on baseline and the placebo slope for EPTo and 2HA, respectively. The sensitivity covariate was signifi-
cant on baseline EPTo values and genetics as a covariate on the placebo slope for 2HA. The analgesic and antihyperalgesic
effects of morphine were pharmacologically distinct as the models had different effect site equilibration half-lives and different
covariate effects. Morphine had negligible effect on 2HA, but significant effect on EPTo.
Pain sensitivity varies substantially among individuals and is
determined by complex interactions between nociception, eth-
nic [1,2], genetic [3], physiological [4,5], psychological [6–8]
and social factors [9]. These interactions together with the
complex pharmacokinetic/pharmacodynamic (PK/PD) relation-
ships for the majority of analgesic drugs explain the less than
straightforward and predictable outcome of pharmacological
pain treatment.
Strong opioids are generally considered efficacious key
players in the management of high-intensity acute and chronic
pain, and opioids are known to possess important antihyperal-
gesic efficacy. However, opioid therapy is also associated with
development of tolerance and a paradoxically increased sensi-
tivity to pain, that is opioid-induced hyperalgesia [10,11]. This
is obviously of great clinical concern as opioid therapy per se
may aggravate pain not only following surgical procedures but
also in chronic pain patients jeopardizing adequate pain con-
trol [10].
Due to the complex actions of opioids, treatment for pain in
the clinical setting often bears resemblance with a trial and
error process. However, as population PK/PD modelling char-
acterizes the relationship between drug concentration and
effect for the typical individual in the population; in addition,
considering specific factors involved in individual patients’
responses from the population mean, PK/PD modelling may
provide a basis for an evidence-guided therapy for the individ-
ual patient [12]. In clinical pain, a number of confounding fac-
tors are present. Human experimental pain models may be
preferable adjuncts in defining the underlying mechanisms, as
the duration, frequency and intensity of nociceptive input can
be minutely controlled in an experimental setting, resulting in
substantially fewer variables confounding pain measures [13].
The analgesic effects of opioids mainly result from activa-
tion of opioid receptors located in the central nervous system
(CNS) at both spinal and supraspinal levels. Peripherally med-
iated suppression of sensitized nociceptors by opioids has been
reported, but the absence of antihyperalgesic effects in clinical
studies suggest that the role of opioids inhibiting central
sensitization is of minor importance [14]. Acute receptor
desensitization via uncoupling of the receptor from G-proteins,
up-regulation of the cAMP pathway, activation of the
N-methyl-D-aspartate (NMDA)-receptor system, as well as
activation of descending facilitation, have been proposed as
potential mechanisms underlying opioid-induced hyperalgesia
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[11]. Furthermore, experimental studies and clinical observa-
tions suggest a possible role for l-receptor agonists to induce
hyperalgesia [10,11]. Therefore, different mechanisms have
been proposed for opioid-induced analgesia and antihyperalge-
sia, which may result in different pharmacodynamic profiles
of the analgesic and antihyperalgesic effects [15].
Polymorphisms in the gene expressing the l-opioid receptor
(OPRM1) have been associated with differences in pain percep-
tion and have been recognized as an important element in
human pain sensitivity. The relationships between A118G sin-
gle-nucleotide polymorphism (SNP), altered pain thresholds
and analgesic responses have been well characterized. Although
a number of studies have reported decreased pain thresholds
and increased pain responses associated with the G118 allele
[16,17], contradictory results have recently been reported [18].
Therefore, the hypothesis that A118G, single-nucleotide poly-
morphism, in the OPRM1 could explain the interindividual dif-
ferences in the analgesic response was explored.
The aim of this study was to model the analgesic and anti-
hyperalgesic responses after intravenous administration of
morphine, a full l-receptor agonist, in healthy volunteers and
to examine whether different pharmacodynamic profiles of the
analgesic and antihyperalgesic effects of morphine exist. A
secondary aim was to investigate the influences of demo-
graphic, pain sensitivity and genetic variables on between-sub-
ject variability in pharmacokinetics and pharmacodynamics of
morphine in human experimental pain models.
Subjects, Design and Methods
The study protocol was approved by the Regional Ethics
Committee (H-2-2010-115), Danish Medicines Agency, Dan-
ish Data Protection Agency and registered at ClinicalTri-
als.gov (NCT01296334). The study was approved as a part of
the study ‘morphine- and buprenorphine-induced analgesia
and antihyperalgesia in a human inflammatory pain model: a
double-blind, randomized, placebo-controlled, 5-arm, cross-
over study’ [19]. The study was conducted according to the
guidelines for Good Clinical Practice (GCP) and audited by
the GCP Unit of Copenhagen University Hospital.
Subjects.
Healthy volunteers were recruited from participants in a prior
study by Ravn et al.[20]. Inclusion criteria were 20–40 years
of age. Exclusion criteria were insufficient proficiency in Dan-
ish, participation in other clinical trials 4 weeks prior to this
study, skin lesions on the lower leg, intake of any medication
48 hr prior to the investigation, intake of analgesics 7 days
prior to the investigation (except paracetamol p.n.), allergy to
morphine, buprenorphine, hydrocortisone, ondansetrone or
DHB, current or former drug abuse, smoking, body mass
index (BMI) > 28 kg/m2 and in females, pregnancy or plan-
ning of pregnancy or no use of contraception. Following ver-
bal and written information, all volunteers provided written
informed consent before inclusion. All volunteers had a rou-
tine medical examination by a physician prior to inclusion.
Design.
The study was a randomized, placebo-controlled, double-
blind, 5-arm, cross-over study.
Several psychophysiological pain tests were performed as
previously described [19]. The electrical pain tolerance (EPTo)
and secondary hyperalgesia (2HA) were further examined in
the present PK/PD analyses. Based on the data from a previ-
ous trial [20], 100 subjects were categorized as low-, interme-
diate- or high pain-sensitive subjects based on their pain
ratings (VAS) during a heat injury (47°C, 7 min., area
12.5 cm2). The low- and high pain sensitive subjects (the sub-
jects, divided into males and females, with the 33% lowest
and highest ratings) were offered participation in the present
study (fig. 2).
Electrical pain tolerance and 2HA were measured during
baseline (before drug infusion) and at three post-burn (PB)
measurements at time (min.) 205, 265 and 325. The infusion
rate was decreased after 15 min. and infusion was discontin-
ued after 210 min., after the first post-burn (PB1) measure-
ment (fig. 1).
Methods.
Electrical pain tolerance. Transcutaneous electrical stimuli
were applied using a computerized, constant current stimulator
(PainMatcher, Cefar Medical AB, Lund, Sweden) [21]. The
stimulator delivered square-wave impulses with a frequency of
10 Hz and an amplitude of 15 mA. The stimulation intensity
was automatically modulated by increased pulse width, in
4 lsec. increments, from 4 to a maximum of 396 lsec. The
subject pinched the two opposed rubber electrodes between
the non-dominant thumb and index finger. By holding a
steady grip on the electrodes, an incremental increase in the
electrical energy was delivered. When releasing the pinch
grip, an arbitrary value between 1 and 100, reflecting the
energy delivered, was registered. The subjects were told to
release when their pain tolerance was reached. The test had a
maximum obtainable value of 100.
Secondary hyperalgesia. The area of secondary hyperalgesia
in normal skin surrounding the area of the heat injury was
determined with a calibrated nylon filament {nominal value
18 [0.89  0.05 N (mean  S.D.)], Stoelting, IL, USA} [22].
The border was determined by stimulating in eight radial lines
each separated by an angle of 45° converging towards the
centre of the heat injury. The subjects reported the occurrence
of a definite uncomfortable change in sensation to a burning
Time (min.)60 120 180 240 300 3600
Baseline PB1       PB2        PB3
Heat injury
Drug infusion
Fig. 1. Study flowchart. Illustration of time for baseline measure-
ments, the heat injury and post-burn 1, 2 and 3, drug infusion
(15 min. loading dose follow by 195 min. maintenance dose) and
times for blood sampling (indicated by stars). Abbreviations: PB, post-
burn (at 1, 2 and 3 hr after the heat injury)
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or stinging sensation. The secondary hyperalgesia areas were
calculated using a computer-based vector algorithm (Canvas
12.0, ACD Systems International, Victoria, Canada). The area
of the thermode (12.5 cm2) was the minimum obtainable
value of the test.
Study drug.
Morphine (20 mg/ml; Morphine SAD) was mixed with
480 ml of 0.9% saline. Morphine (10 mg and 20 mg) and pla-
cebo (0.9% saline) were administered as i.v. infusions over a
210-min. period. The dose was administered according to the
following infusion regimen: between 0 and 15 min., one-
fourth of the dose was infused; the remaining three quarters of
the dose was infused between 15 and 210 min. Thus, the infu-
sion rates were 166.7 lg/min. and 333.3 lg/min. during the
first 15 min., and 38.5 lg/min. and 77.0 lg/min. during the
subsequent 195 min. (10 and 20 mg, respectively). The target-
controlled infusion regimens were chosen to obtain steady-
state conditions (until 1 hr after the heat injury, PB1). Simula-
tions based on a morphine model [23] were performed with
Berkeley Madonna (v. 8.3.18, UC, Berkeley, CA, USA) to
develop these dose regimens. The dose regimens were chosen
as an attempt to minimize potential concentration-dependent
adverse events, especially nausea and vomiting, and at the
same time, to reach a significant difference between the high
and low doses.
As a preventive measure, antiemetics (25 mg hydrocortisone
succinate and 2 mg ondansetron) were administered initially
to all subjects and a drip of 1000 ml 5.5% isotonic glucose
was administered intravenously to prevent fasting symptoms.
The randomization, blinding and packaging of drugs were
performed by Herning Hospital Pharmacy, who used the
second generator at randomization.com. The second generator
creates random permutations of treatments for situations where
subjects receive all of the treatments in random order. The
packaging was identical for all study drugs, and the drug solu-
tions were prepared 1–12 hr before use by pharmaceutically
trained staff not involved in other parts of the study.
Vital signs.
An electrocardiogram was taken before morphine infusion was
initiated, and exact values of blood pressure, pulse rate, respira-
tory rate and arterial oxygen saturation were registered before
each blood sampling and monitored during the entire sessions.
Blood sampling.
Eight blood samples (10 ml each) were collected before drug
administration and 15, 60, 95, 140, 200, 260 and 320 min.
after initiation of drug administration. After centrifugation at
1400 9 g for 10 min., plasma was separated and stored at
20°C until drug analysis.
Quantification of morphine.
The analytes and the internal standard (morphine-D3) were
extracted from plasma using solid-phase extraction (SPE). Chro-
matographic separation from other constituents of the sample
was achieved by ultra performance liquid chromatography (Ac-
quity, Waters, Waters Corp., Milford, CT, USA), followed by
tandem mass spectrometry (MS/MS) detection (API 5000,
33 33ENROLLMENT Assessed for eligibility
Males
30 29 Eligible
Excluded:
• Exceeded upper age limit (1)
Dropped out:
• Lost to follow-up (3)
Excluded:
• Non-compliant (2)
Dropped out:
• Lost to follow-up (1)
Dropped out:
• Compensation too low (1)
• Residence abroad (1)
• Pregnancy or lack of 
contraceptives (4)
• Lack of time (2)
• Reason not reported (6)
Excluded:
• Medical reason (1)
Dropped out:
• Compensation too low (1)
• Residence abroad (5)
• Lack of time (3)
• Reason not reported (3)
16 16INCLUSION, DAY1
Excluded:
• Medical reason (1)
Dropped out, discontinued 
day 1:
• Adverse events (1)
• Feeling discomfort (1)
15
Dropped out, completed day 1:
• Adverse events (1)
13DAY 2 - 4
Excluded, lacking the last 
session:
• due to high drug liking score 
(1)13 14DAY 5 
Female
Fig. 2. Subject flow diagram. Illustration of patient enrolment, inclusion, the two study days and enrolment- and eligibility analysis.
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Applied Biosystems/MDS Sciex, Concord, Ontario, Canada).
The analytes were separated by an Atlantis dC18 (5 lm,
150 9 2.1 mm ID) column at ambient temperature, using 8%
aqueous ammonium formate (10 mM) in methanol as the eluent
at a flow rate of 0.5 ml/min. turbo-ion spray in positive ion
mode with selected reaction monitoring mode (MRM). The
retention time for morphine was 2.8 min. Morphine and mor-
phine-D3 were detected at parent/daughter molecular mass of
286.2/152.1 and 289.2/152.1 m/z, respectively, using a cone
voltage of 5000 V and a collision energy of 4.0 eV. Peak areas
correlated linearly (r2 > 0.998  0.0005; Mean  S.D., n = 3)
with morphine concentrations in the range 20–1000 ng/ml.
Accuracy and precision (mean  S.D., n = 6) of back-calcu-
lated morphine concentrations from plasma calibration standards
were 20.1  0.15, 39.6  0.46, 99.9  3.5 ng/ml,
204  3.4 ng/ml and 1020  11.7 ng/ml for the 20, 40, 100,
200 and 1000 ng/ml calibration standards, respectively. To
avoid censoring of data, the data were re-analysed with the stan-
dard curved extrapolated through zero, and morphine plasma
concentrations between 3 and 20 ng/ml were included.
Genetic analyses.
Blood samples were taken to perform an allelic discrimination
assay in regard to the single-nucleotide polymorphism (SNP)
118 in the OPRM1 gene, using polymerase chain reaction
(PCR) technique. The polymorphism was determined in 27 of
the 28 subjects, and the subjects were characterized as being
either homozygotes (AA) or heterozygotes (AG). The test was
repeated with no divergence. The analyses were performed at
the University Hospital of Copenhagen.
PK/PD analysis.
The PK/PD analyses were performed using nonlinear mixed
effect (population) modelling with the ‘NONMEM’ software
(Version 7 level 2.0, ICON Development Solutions, Ellicott
City, MD, USA) with the Wings For NONMEM interface
available from Nick Holford (version 720; http://wfn.source-
forge.net/). The R data analysis language (version 2.14.1) was
used for most graphical output and data analysis [24].
Population parameter variability (PPV) was described using
either an exponential distribution, which approximates a log-
normal distribution:
hi ¼ h  egi ð1Þ
or a normal distribution
hi ¼ hþ gi; ð2Þ
where hi is the value of the parameter for the ith subject, h is
the typical value of the parameter in the population, and gi is
a random vector with a mean of zero and a normal distribution
with a variance-covariance matrix of between-subject variabil-
ity (BSV) x. If data were available on more than one occa-
sion, then between-occasion variability (BOV) was also tested
as a random effect. For example, assuming log-normally dis-
tributed parameter:
hi;k ¼ h  egiþgi;k; ð3Þ
where hi, k is the value of the parameter for the ith subject on
the kth occasion.
Residual unexplained variability (RUV) model was
described using a combination of additive and/or proportional
models or an exponential model.
Selection criteria for the final models were based on stan-
dard diagnostic plots and parameter precision estimates. For
the PK model development, a drop of 3.84 in objective
function value (OBJ) for one nested parameter was consid-
ered a significant improvement in model fit (p < 0.05). The
Akaike information criterion was calculated from the OBJ
obtained from NONMEM (AIC = OBJ + 2 9 npar, where
npar is the total number of model parameters). ΔAIC more
than -2 was used as indicator of improved model fit [25]
for placebo and PD models. Evaluation of final models
employed visual predictive checks (VPC) based on 500 sim-
ulations of the index dataset using the final model and its
parameter estimates with nominal sampling times from the
original data.
Pharmacokinetic modelling. The 1-, 2- and 3-compartment
models were fitted to the morphine plasma concentration–time
data. The covariate analyses included age, sex and BMI as
covariates on clearance (CL), volumes (V1) and
intercompartmental clearances (Q). Weight was tested as a
covariate on each parameter individually or as allometrically
scaled on all parameters.
Pharmacodynamic modelling. Using the final pharmacokinetic
model, Bayesian MAP (maximum a posteriori probability)
estimates of the PK parameters for each individual subject
were used to provide the concentrations of morphine used in
the PD analyses (i.e. a sequential PK–PD approach).
Important aspects of modelling drug effects on pain metrics
include a dataset with a realistic representation of the baseline
(time zero, drug-free) distribution of the pain metric and a
realistic representation of the time course of the metric in the
placebo group. The latter is necessary as pain metrics may
demonstrate time-dependent changes in the placebo group due
to accommodation or sensitization to the stimulus. Avoiding
accounting for these changes may confound estimates of any
concentration–effect relationship.
Baseline distribution. Inspection of the baseline pain metric
data showed that pain metrics were censored. Some EPTo
readings were at the maximum obtainable value of 100, while
some readings of 2HA were at the minimum possible value of
12.5 cm2. Furthermore, some subjects on occasions had
readings at the maximum (ceiling) or minimum (floor) value
throughout the measurement period. Initial investigations using
censored baseline distributions were unsatisfactory as these
occasions could not be used to estimate model parameters.
These occasions were deemed to be indescribable [26]. To
extract the maximum possible information from the data,
mixture models were used to estimate describable data from the
© 2014 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society)
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different populations as summarized in table 1. Allocation into
the different populations was based on the observed data and
was not estimated. Model predictions in the describable data
were constrained to be less than 100 for EPTo and > 12.5 for
2HA. The 2HA data were log-transformed to approximate a
normal distribution.
Placebo time course. The models for the time course for the
placebo response were systematically examined to evaluate
whether there were changes over time from baseline, included no
change, as well as linear and quadratic functions over time in the
change from baseline. The following models were examined:
No change model: no change in effect,
Effectplacebo ¼ BASE; ð4Þ
where BASE = baseline value. The no change model allowed
baseline variation between subjects but with no change over
time. Furthermore, genetics and sensitivity as covariates on
baseline were tested.
Linear model: linear change in effect with time,
Effectplacebo ¼ BASEþ SLPplacebo  TIME; ð5Þ
where SLPplacebo = slope of the change in effect over time.
The linear model tests whether time linearly influences the
effect after placebo. The linear model was tested with or with-
out population variability on the slope term. Importantly, a
model was tested that fixed the slope to 0 (i.e., the population
mean did not change over time) with normally distributed
between-subject variability still present. This model tested the
hypothesis that although, on average, there is no consistent
change in the pain metric, it allows for subjects to have
changes in pain metric over time in either positive or negative
directions. Furthermore, genetics and sensitivity as covariates
on baseline and slope were tested.
Quadratic model: quadratic change in effect with time,
Effectplacebo ¼ BASEþ SLPplacebo  TIME
þ SLPplacebo2  TIME2;
ð6Þ
where SLPplacebo2 = slope 2. The quadratic model tests whether
there is a curvature in the effect–time relationship. Furthermore,
the quadratic model was tested with or without population vari-
ability on the slope terms. Genetics and sensitivity as covariates
on baseline and slopes and mixture models were tested.
PK/PD modelling.
The models best suited to describe the relationship of the pla-
cebo response for the two psychophysiological tests were used
to examine the response of these tests parameters to the drug
with the assumption that the drug effect was additive;
Effect ¼ Effectplacebo þ Effectdrug; ð7Þ
or proportional to the placebo response:
Effect ¼ Effectplacebo  ð1þ EffectdrugÞ: ð8Þ
Models were also tested with and without effect compart-
ments to test the hypothesis that there was a delay in the
response relative to changes in concentration:
dC0effdt ¼ ke0  ðCplasma  CeffÞ; ð9Þ
where ke0 is a first-order distribution rate constant describing
the rate of change of morphine concentration in the effect
compartment (Ceff) which is assumed to represent the concen-
tration of the drug at a hypothetical biophase site of action. In
the case of models without an effect compartment, then Ceff is
simply equal to the plasma morphine concentration (Cplasma).
In addition, as the placebo response is still present during
morphine administration, BOV was also tested in parameters
describing a change in effect in the placebo submodel.
The models for the time course for the drug response were
systematically examined included linear, Emax and sigmoid
Emax models, and models were tested with proportional and/or
additive residual error models.
Linear model with effect compartment:
Effectdrug ¼ SLPmorphine Ceff ; ð10Þ
where SLPmorphine = the slope of the morphine effect.
Emax model with effect compartment:
Effectdrug ¼ ½Emax  Ceff=ðCeff þ EC50Þ; ð11Þ
where Emax = the maximum achievable effect and EC50 is the
drug concentration associated with half the maximum effect.
Table 1.
Ceiling- and floor effect. Different scenarios present for data affected by ceiling- or floor effect and the number of subjects affected by the given
scenario. ʻIndescribableʼ indicates that the maximum or minimum values were reached in all four tests (pre-burn and PB1-3) following administra-
tion of placebo, low-dose morphine and/or high-dose morphine. ʻDescribableʼ indicates that at least one of the four tests reached a value not deter-
mined by the cut-off limit of the tests.
Placebo Morphine, low dose Morphine, high dose Number of Subjects
EPTo Describable Describable Describable 26
Describable Indescribable Indescribable 1
Indescribable Describable Indescribable 1
2HA Describable Describable Describable 19
Indescribable Describable Describable 4
Describable Indescribable Describable 1
Describable Indescribable Indescribable 2
Indescribable Indescribable Indescribable 2
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The Emax model is used to determine whether the concentra-
tion–effect is nonlinear.
Sigmoid Emax model with effect compartment:
Effectdrug ¼ ½Emax  Ceffn=ðCeffn þ EC50nÞ; ð12Þ
where n = the Hill coefficient. The Sigmoid Emax model is
used to determine whether the concentration–effect is sigmoi-
dal in shape.
The following covariates were tested for their effect on
model parameters for EPTo and 2HA; weight and BSA (body
surface area) were tested using a power function, while the
categorical covariates (genetics and sensitivity) were tested
using a proportional change model.
Results
Subjects.
The intention-to-treat (ITT) and per-protocol (PP) groups were
32:32 (males:females) and 14:13, respectively (fig. 2).
Three subjects did not complete the study; one subject did
not complete the last treatment (low-dose morphine) as he was
excluded based on the study exclusion criteria of too high
drug liking score [19], one subject withdrew due to feeling
uncomfortable before drug infusion, and one subject due to
adverse events. Data from these last two subjects were not
included in the analyses. Thus, the analyses included 28 sub-
jects for placebo and high-dose morphine and 27 subjects for
low-dose morphine.
Significant sex differences were seen in regard to height
and weight (p < 0.0001) and in age distribution (p = 0.012),
but there were no significant sex differences in body mass
index (BMI; p = 0.328, table 2).
In the genetic assays, (SNP) 118 in the OPRM1 gene, three
subjects were heterozygote (AG). Data were not obtainable in
one subject due to missing blood sample; this subject was
assumed to be homozygote (AA).
Morphine pharmacokinetics.
A two-compartment linear model gave the best description of
the plasma concentration–time profiles of morphine, compared
to a one-compartment model, which failed to describe the ter-
minal phase. A three-compartment model was rejected as it
effectively collapsed back to two-compartment model with
very low values for the intercompartmental clearance to the
third compartment. Moreover, no significant difference in the
residual plots between two- and three- compartment models
was observed. The final two-compartment base model
included a proportional residual error to the morphine plasma
concentration, and random effects on CL, V1 and Q. The
inclusion of allometric scaling for weight provided an
improvement over the base model (DOBJ = 14.9). The pop-
ulation pharmacokinetic parameter estimates of the final PK
model are presented in table 3.
All population parameters were estimated within acceptable
precision (3.1–27.4% S.E.) as were the estimates for random
effects (26.1–57.7% S.E.). Interindividual variability ranged
between 14.5% and 83.5% with the highest variability found
for V1. The model had a residual unexplained variability of
15.7%. The model had acceptable shrinkage values for CL
and V1 (4.04% and 24.2%, respectively), but slightly high val-
ues for Q (52.9%). Omitting interindividual variability on Q,
however, gave a significantly worse model-fit to data
(DOBJ = 3.9), and this random effect was therefore kept in
the model in spite of the high shrinkage value. This was fur-
ther justified as the PK model was mainly intended to provide
MAP Bayes estimates for the PD modelling stage. There was
an acceptable agreement between the observed and individu-
ally predicted concentrations (fig. 3).
The VPC based on 500 simulations of the final PK model
suggested an acceptable fit of the model to the morphine
plasma concentration–time data for both doses (fig. 4).
Placebo response.
Several subjects were affected by ceiling- or floor-effects
(indescribable data): the tests were affected by these limita-
tions in 11 of 56 cases (table 1).
The modellings of the EPTo and 2HA during the placebo
treatment were best described by a linear model and quadratic
model, respectively. The best fit for the model for EPTo was
obtained with the numbers of non-responders (subjects not
reaching their electrical pain tolerance due to ethical and
Table 2.
Anthropometric data. Age (years), height (cm), weight (kg) and BMI
(kg/m2) reported as mean, with standard deviation in brackets
(n = 28). Abbreviation: BMI, body mass index.
Sex Age (years) Height (cm) Weight (kg) BMI (kg/m2)
Females 23.2 (2.0) 168.3 (6.2) 64.7 (7.4) 22.9 (2.6)
Males 26.7 (4.3) 184.4 (7.5) 81.0 (9.4) 23.8 (2.2)
Females
and males
25.1 (3.8) 176.9 (10.6) 73.4 (11.8) 23.4 (2.4)
Table 3.
Parameter estimates and standard error (%) of the final pharmacoki-
netic model. Abbreviations: V1, central distribution volume; CL,
apparent clearance; V2, peripheral distribution volume; Q2, intercom-
partmental clearance between V1 and V2; WT, subject’s weight;%
S.E., standard error the parameter estimates.
Model parameter Estimates % S.E. % Shrinkage
CL θ1 9 (WT/70)^0.75
V1 θ2 9 (WT/70)
Q θ3 9 (WT/70)^0.75
V2 θ4 9 (WT/70)
Population estimates
θ1 (L/min) 1.37 3.1
θ2 (L) 19.4 27.4
θ3 (L/min) 2.73 5.3
θ4 (L) 134 6.0
Interindividual variability (%CV)
xCL 14.5 26.1 4.04
xV1 83.5 41.3 24.2
xQ 19.4 57.7 52.9
Residual variability
e (%CV) 15.7 22.1 6.2
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medical limitations of the testing procedure) fixed to that from
the observed data, and with sensitivity (low- versus high pain
sensitivity) included as a covariate on baseline. The best fit
for the model for 2HA was obtained with the genetic variable
included as a covariate on the slope of the placebo response.
Electrical pain tolerance model (EPTo).
The model discrimination process showed clear evidence for
adding BOV on baseline (DAIC = 13.3) and an effect-delay
compartment (ke0; DAIC = 91.7). A linear drug effect to the
final model for EPTo improved the fit compared to no drug
effect (DAIC = 12.9). However, more complex drug effect
models did not show further improvement (DAIC > 25), were
unstable or did not converge. A drug effect proportional to the
placebo effect was preferred over an additive relationship
(DAIC = 27). The sensitivity covariate was significant on
the baseline measurements (DAIC = 2.7), but not on the
drug effect slope parameter (DAIC = 0.5). Population vari-
ability or a genetic covariate on the drug effect slope parame-
ter failed to improve the fit of the model (DAIC = 5.3 and
DAIC = 1.6, respectively). Box-Cox transformation was inves-
tigated to allow skewness in the baseline distribution; how-
ever, this improvement was not substantial (DAIC = 2.1).
Population parameters for the EPTo final model were esti-
mated within acceptable precision (11.0–40.3%S.E.) as was
the precision for interindividual variability (23.0–62.4%S.E.)
(table 4). Interindividual variability ranged between 19% and
46% with the highest variability found for the slope for the
morphine effect. The effect-delay rate constant, ke0,
(0.000243 min1) resulted in a relatively long equilibration
t1/2 (47.5 hr) but was estimated with a good precision (10.9%
S.E.). Removing the effect-compartment from the final model
gave a significantly worse fit of the model to the data
(DOBJ = 98).
The baseline EPTo had a relatively high population parame-
ter variability of 46%, of which BOV account for approxi-
mately 19%. Figure 5 shows the baseline distribution for the
observed and individual predicted values for EPTo.
The model showed good agreement between the observed
and individual predicted effects (fig. 6).
Secondary hyperalgesia model.
Based on the defined model development criteria, the best fit
for 2HA was a linear concentration–effect model with an
effect-compartment delay including BOV and genetics as a co-
variate on the placebo slope and baseline fixed to log
(12.5 cm), which is the area of the thermode. The model had
a significant linear drug effect with interindividual variability
Fig. 3. Observed morphine versus individual predicted morphine con-
centrations
Fig. 4. Visual predictive check. Observed and predicted morphine plasma concentration–time profiles after i.v. infusion of a low- and high-dose of
morphine, using the final PK model with weight as covariate. Dashed lines are median and the 5% (lower) and 95% (upper) confidence intervals
for the observed data. Dotted lines are median and the 5% (lower) and 95% (upper) confidence intervals for the simulated data.
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on this parameter, but more complex drug effect models did
not show further improvement (DAIC > 20), were unstable or
did not converge. A drug effect proportional to the placebo
effect was preferred over an additive relationship
(DAIC = 46.9). Compared to the final model, estimating
baseline (DAIC = 2.2), or allowing PPV with or without
BOV, on baseline worsened the fit (DAIC >200) and resulted
in unstable models. Similarly when assuming a normally dis-
tributed PPV (DAIC = 569) or removing BOV on drug effect
(DAIC = 119). Removing the effect of genetics on drug effect
resulted in a marked worsening of model fit (DAIC = 51.6).
Removal of the effect compartment delay (ke0) resulted in a
model which terminated abnormally over a wide range of ini-
tial estimates.
The population estimates and interindividual variability for
the preferred model for 2HA are listed in table 5.
Population parameters for 2HA were estimated within the
precision range of 1.9–65%, except genetics as a covariate on
the placebo slope (SLPplacebo), which had a %S.E. of 148.
However, removing this covariate from the model caused an
increase of 49 in OBJ, and it was therefore kept in the final
model. Interindividual variability ranged between 63% and
345%, with the highest variability found for the slope on
baseline, and with interindividual variability estimates
between 0.5% and 57.8% S.E. The distribution rate constant,
Table 4.
Population estimates and interindividual variability for the preferred
model of EPTo. t½, ke0 calculated as ln(2)/ke0. Abbreviations: EPTo:
electrical pain tolerance, BASE: baseline, SLPplacebo: linear slope on
placebo, SLPMOR: slope on morphine, SensBASE: sensitivity covariate
on baseline, ke0: effect compartment rate constant, t½,ke0: effect site
equilibration half-life, half-time, and e: proportional residual error.
Model parameter Estimates % S.E.
BASE θ1 9 (1 + SensBASE)
SensBASE θ2
SLPplacebo θ3
SLPMOR θ4
ke0 θ5
Population estimates
θ1 19.7 11.0
θ2 0.784 40.3
θ3 0.00792 16.3
θ4 0.213 28.5
θ5 (min
1) 0.000243 10.9
t½, ke0 (h) 47.5
Population parameter variability (PPV)
xPPVBASE (%CV) 45.6 23.0
xBOVBASE (%PPV) 19 57.9
x SLPMOR (S.D.) 0.145 62.4
Residual variability
e (S.D.) 0.172 21.3
Fig. 5. Baseline distributions for EPTo. Observed (dashed) and indi-
vidual predicted (solid) baseline data. Abbreviation: EPTo, electrical
pain tolerance [arbitrary scale (0–100)].
Fig. 6. Observed and individual predicted data for EPTo (top) and
2HA (bottom). Data from placebo (open circles), low dose (triangle)
and high dose (cross) of morphine. The solid lines indicate a line of
slope 1, and the dashed line is a less smoothed line. Abbreviations:
EPTo, electrical pain tolerance; 2HA, secondary hyperalgesia area.
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ke0, was slightly high (0.00756 min
1) but was estimated
well (1.9%S.E.). The model had a proportional residual error
of prediction of 6.9%. The model showed good agreement
between the observed and individual predicted effects (fig. 6),
although with a slight tendency towards under predictions at
the high end of the scale for 2HA and the model failed to
reach the non-responders.
Discussion
In the present study, population PK/PD models were devel-
oped to characterize the analgesic and antihyperalgesic effects
of morphine, in addition to delineate a placebo-response model
in healthy volunteers.
Morphine pharmacokinetics.
The population pharmacokinetics of morphine after intrave-
nous administration was successfully described by a two-com-
partment distribution model with first-order elimination from
the central compartment. Typical values and interindividual
variability for the population PK parameters were estimated
with acceptable precision and within the range of that reported
in previous literature [23,27] for a 70-kg person. Unexplained
interindividual variability was significantly reduced by inclu-
sion of body-weight allometrically scaled to clearances and
volumes, suggesting that a more uniform morphine exposure
is achieved in healthy volunteers, when doses are weight-
adjusted accordingly.
Analgesic versus antihyperalgesic effect.
One of the primary aims of the study was to evaluate the PK/
PD relationship of morphine using an experimental model of
analgesic (ETPo) and antihyperalgesic (2HA) responses. The
results from the study corroborate the analgesic effects of mor-
phine observed in a number of studies [28–30] using heat
models (heat injury, heat-capsaicin, brief thermal stimulation),
but the lack of antihyperalgesic effect of morphine was origi-
nally unexpected as up to 85% reductions in hyperalgesia
areas has been reported after use of morphine [29]. However,
the PK/PD analyses were in accordance with the findings from
the statistical analyses reported earlier [19].
For ETPo, a linear model, and for 2HA, a quadratic model,
were used to describe the time–response relationship for pla-
cebo treatment, signifying the importance of including this in
the evaluation of the morphine response in the experimental
models to avoid bias, as the responses to the stimuli were not
constant over time.
A linear concentration–effect model incorporating an effect-
compartment delay relative to changes in plasma concentration
provided the best fit to both the ETPo- and 2HA response.
Blood samples were taken at fixed time-points during each
session; more individually scattered sample times would have
been preferable as more modelling points would have been
available. In spite of the sparse sampling times, acceptable
parameter precision was obtained for the ETPo model. After
accounting for the placebo response, a significant effect of
morphine was found on the ETPo response in terms of higher
pain threshold with increasing morphine concentration. How-
ever, compared to data from previous studies, a surprisingly
long effect-compartment half-life was suggested for the anal-
gesic response (47.5 hr). In healthy volunteers and patients,
morphine has been reported to have a t½, ke0 around 0.7–7 hr
with various quantitative sensory testing (QST) response types
[31], including electrical skin stimulation [32]. It could be
speculated that the active metabolite M6G may contribute to
the prolonged t½, ke0 in the present study. However, given
M6G’s relatively low appearance rate [27] and long effect site
equilibration with an equilibration half-life (t½, ke0) in the
range of 6–8 hr [31,33,34] combined with the condition that
the last PD measurements and blood samples were taken at
5.5 hr, it is unlikely that a significant contribution from M6G,
in relation to the analgesic and antihyperalgesic effects, was
present. A study design with more response assessment times
and longer study duration would likely have been beneficial if
the scope was to determine the most accurate t½, ke0 for mor-
phine, in the electrical pain tolerance model. However, the
large drop in OBJ signifies the importance of having an effect
compartment in the model, to describe to present dataset.
Individual pain sensitivity (determined by the pain intensity
during the burn injury) was significantly positively correlated
with baseline score for ETPo, but did not appear to have a
significant relationship with the drug response slope. This sig-
nificant finding at baseline confirms the results from the previ-
ous study [20] in which EPTo was one of the predictive
variables of the heat injury from which the subjects were cate-
gorized as either low- or high pain-sensitive subjects.
Table 5.
Population estimates and interindividual variability for the preferred
model of 2HA. t½, ke0 calculated as ln(2)/ke0. Abbreviations: 2HA,
secondary hyperalgesia; BASE, baseline; SLPplacebo, linear slope on
placebo; SLP2placebo, quadratic slope on placebo; SLPMOR, slope on
morphine; GenBASE, genetic covariate on baseline; ke0, effect compart-
ment rate constant; t½,ke0, effect site equilibration half-life; half-time,
and e: proportional residual error.
Model parameter Estimates % S.E.
BASE θ1
GenSLP θ2
SLPplacebo θ3
SLP2placebo θ4
SLPMOR θ5
ke0 θ6
Population estimates
θ1 (cm
2) Log(12.5) = 1.1 8.8
θ2 0.00453 11.0
θ3 0.000102 64.7
θ4 0.00266 147.7
θ5 0.0853 1.9
θ6 (min
1) 0.00756
t½, ke0 (h) 1.5
Population parameter variability (PPV)
xPPVSLPplacebo (%CV) 12.3 250
xBOVSLPplacebo (%PPV) 57.8 345
x SLPMOR (S.D.) 0.45 63.1
Residual variability
e (S.D.) 6.9 77.8
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In relation to the antihyperalgesic response, no significant
effect of morphine was suggested by the pharmacodynamics
drug slope (SLPmorphine), with a 95% CI that entails zero
[0.001; 0.006]. A significant impact of the examined SNP
variants was found on SLPplacebo (8% increase), suggesting
that the AG variant causes increased hyperalgesia.
The EPTo and 2HA analyses of the present study were
complicated by the maximum and minimum obtainable values.
EPTo demonstrated ceiling effects and 2HA demonstrated
floor effects. Hence, the data did not contain sufficient infor-
mation to estimate the maximum analgesic and antihyperalge-
sic effects of morphine. However, the impact was limited as
the data only were deemed indescribable in cases where all
four measurements reached the maximum or minimum obtain-
able values (table 1).
Thus, in conclusion, a population PK/PD model has been
developed for morphine which indicates that the analgesic and
antihyperalgesic effects of morphine are pharmacologically
distinct entities. Among the investigated covariates, body-
weight has been suggested as significantly associated with the
pharmacokinetics of morphine, while pain sensitivity is signifi-
cantly related to analgesic baseline score and the A118G SNP
on the OPRM1 receptor-expressing gene is associated with an
increased hyperalgesic area.
Using nonlinear mixed effect modelling, this study has
successfully discriminated between analgesic and antihyperal-
gesic pharmacodynamics properties of morphine. Addition-
ally, the population PK/PD modelling approach enabled
identification of important factors explaining interindividual
variability (weight for PK, subject sensitivity and genetics).
The number of subjects was limited by the study design
with the need to include the high and low pain-sensitive
subjects from a previous study. Some of the parameters pos-
sessed relatively high standard errors, which may reflect the
low number of subjects or model misspecification. Also, the
relatively small number of heterozygotes should be taken
into consideration when evaluating the genetic aspects and
the clinical implication. The presented models may be useful
for simulation and design of future trials involving experi-
mental pain models using electric pain stimulation in healthy
volunteers.
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